Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Community
/
United States
/
Pharmaceuticals & Biotech
/
Organon
OGN
Organon
Global Pricing Pressures And Patent Cliffs Will Weaken Margins
AN
AnalystLowTarget
Not Invested
Consensus Narrative from 6 Analysts
Published
01 Jun 25
Updated
09 Aug 25
0
Set Fair Value
0
votes
Share
AnalystLowTarget
's Fair Value
US$9.00
4.9% overvalued
intrinsic discount
09 Aug
US$9.44
Loading
1Y
-55.0%
7D
4.8%
Author's Valuation
US$9.0
4.9% overvalued
intrinsic discount
AnalystLowTarget Fair Value
View Valuation
Narrative
Updates
0
Valuator
Company Info
Notes
AnalystLowTarget Fair Value
US$9.0
4.9% overvalued
intrinsic discount
Future estimation in
3 Years
time period
Past
Future
0
11b
2017
2019
2021
2023
2025
2027
2028
Revenue US$6.2b
Earnings US$1.0b
Revenue
Profit Margin
Future PE
Revenue
% p.a.
0
Decrease
Increase
Current revenue growth rate
1.08%
Pharma revenue growth rate
1.05%
Other Inputs & Calculation
Risk Level (Discount Rate)
Our default considers factors like the company's size, volatility, profitablity and country of operation.
Risk Level (Discount Rate)
%
0
Decrease
Increase
Current discount rate
9.61%
Calculation
US$1.03b
Earnings '28
x
3.09x
PE Ratio '28
=
US$3.18b
Market Cap '28
US$3.18b
Market Cap '28
/
267.48m
No. shares '28
=
US$11.88
Share Price '28
US$11.88
Share Price '28
Discounted to 2025 @ 9.75% p.a.
=
US$8.98
Fair Value '25
